Protagonist Therapeutics, Inc. announced positive topline results from the Phase 2b FRONTIER 1 clinical trial evaluating the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult patients with moderate-to-severe plaque psoriasis (PsO). The trial achieved all primary and secondary efficacy endpoints. Independently, Protagonist continues to utilize its technology platform and know-how to innovate novel oral assets against other biological targets and diseases in which an oral approach can offer significant differentiation and superiority in addressing major unmet medical needs.

The FRONTIER 1 Phase 2b trial (NCT05223868) is a randomized, multicenter, double-blind, placebo-controlled clinical trial that evaluated three once-daily dosages and two twice-daily dosages of JNJ-2113 taken orally. It was designed to assess the efficacy and safety of JNJ-2113 in patients with moderate-to- severe plaque psoriasis. The total duration of the trial was up to 24 weeks which included a screening period of less than or equal to four weeks, a 16-week treatment period, and a four-week safety follow-up period.